Sichuan Kelun-Biotech announced China’s NMPA cleared IND application for SKB-103, a solid-tumor therapy program entering clinical evaluation. The clearance is a direct step toward trial initiation and expands Kelun’s advanced-stage pipeline footprint in oncology. For the broader biotech market, IND clearances in China remain an important barometer of how quickly developers can translate preclinical packages into clinical execution under current regulatory workflows. It also reinforces China’s role as a key launchpad for global oncology programs. Market participants will track subsequent trial registrations, patient population selection, and early safety/tumor response readouts as SKB-103 begins to generate clinical evidence.